Juntendo University · Graduate School of Medicine / Faculty of Medicine · 教授

Research keywords自己免疫疾患・全身性エリテマトーデス・成人発症スティル病・関節リウマチ・抗MDA5抗体陽性皮膚筋炎・生物学的製剤・トシリズマブ・ベリムマブ・グルココルチコイド

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• Hatano R, Nakamura H, Yamamoto A, Otsuka H, Itoh T, Hosokawa N, Yu J, Ranjbar S, Hasegawa Y, Sato T, Dang NH, Ohnuma K, Morimoto S, Sekigawa I, Ishii T, Morimoto C. An abnormal increase in CD26(−)CD28(−) cytotoxic effector CD4 and CD8 T cell populations in patients with systemic lupus erythematosus. Int Immunol. 2025; 37(3):153–171.2025
• Suzuki S, Otani T, Ikeda K, Tamura N, Morimoto S. Immunol Method. Additional benefits of belimumab in chronic phase of systemic lupus erythematosus and efficacy of tacrolimus combination therapy2024 Dec 27:1-7. doi: 10.1080/25785826.2024.2447629.2024
• Suzuki S, Kataoka Y, Otani T, Taniguchi Y, Ikeda K, Tamura N, Morimoto S. Optimal time of starting tocilizumab in acute phase of adult-onset Still's disease and comparison of its efficacy with that of methotrexate: a case series and a review of the literature Clin Rheumatol. 2024 43(3):1245-1251.2024
• Hayakawa K, Fujishiro M, Yoshida Y, Kataoka Y, Sakuma S, Nishi T, Ikeda K, Morimoto S, Takamori K, Sekigawa I. Exposure of female NZBWF1 mice to imiquimod-induced lupus nephritis at an early age via a unique mechanism that differed from spontaneous onset. Clin Exp Immunol. 2022 13;208(1):33-46.2022

• 抗CTGF抗体による新規強皮症治療の可能性の検討

• Official profile